Abstract P081 – Table 1. Summary of real‐world study and randomized controlled trial definitions for PWHIV with M184V/I resistance‐associated mutations receiving DTG+3TC.
Study (cohort)	Proportion with M184V/I	VF definition	M184V/I identification method
Real‐world studies
Hocqueloux 2021 (Dat'AIDS)	105/695 (15.11%)	2 consecutive confirmed VL >50 copies/mL or 1 VL >200 copies/mL	RNA and proviral DNA genotypes (pooling both)
Santoro 2021 (LAMRES)	36/533 (6.75%)	2 consecutive confirmed VL >50 copies/mL or 1 VL >200 copies/mL	RNA and proviral DNA genotypes
Borghetti 2021 (ODOACRE)	48/669 (7.17%)	1 VL ≥1000 copies/mL or 2 consecutive VL ≥50 copies/mL	Historical genotypes; does not specify RNA or proviral DNA
Galizzi 2018 (NR)	47/174 (27.01%)	2 consecutive confirmed VL >50 copies/mL or 1 VL >50 copies/mL followed by treatment modification, or 1 VL >1000 copies/mL	Either RNA or proviral DNA genotypes at baseline (before switch)
Hidalgo‐Tenorio 2019 (DOLAMA)	4/178 (2.25%)	2 consecutive VL >50 copies/mL	Baseline RNA genotype
Randomized controlled trials
ART‐PRO	17/41 (41.46%)	VL ≥50 copies/mL	Proviral DNA genotype
SOLAR 3D	50/100 (50.00%)	VL ≥50 copies/mL	Historical genotypes; does not specify RNA or proviral DNA
TANGO	4/322 (1.24%)	VL ≥50 copies/mL	Proviral DNA genotype
DOLULAM	17/27 (62.96%)	VL ≥200 copies/mL	RNA and proviral DNA genotypes
SALSA	5/192 (2.60%)	VL ≥40 copies/mL	Proviral DNA genotype

DTG+3TC, dolutegravir + lamivudine; NR, not reported; PWHIV, people with HIV‐1; VF, virologic failure; VL, viral load.